Building Bridges Between Treatment Centers and Community Practices

Target Audience

The educational design of this activity addresses the needs of community-based allergy/clinical immunology, medical dermatology, hematology/oncology, and gastroenterology clinicians (MDs, NPs, PAs) involved in the management of patients with nonadvanced systemic mastocytosis (SM).

Program Overview

SM is a rare and underrecognized clonal mast cell disorder that often presents with heterogeneous symptoms, leading to diagnostic delays, significant quality-of-life burdens, and suboptimal care. This BRIDGE SM regional webinar series is designed to close critical knowledge gaps among community-based clinicians involved in the diagnosis and management of nonadvanced SM. Through an in-depth review of pathophysiology, clinical presentation, diagnostic tools, and treatment options—including US Food and Drug Administration (FDA)-approved targeted therapies—participants will gain actionable insights into improving patient outcomes. Regional perspectives will highlight how SM diagnosis and care pathways may vary across diverse practice settings and geographic areas in the US.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe the pathophysiology of nonadvanced SM, including the role of driver mutation(s) in mast cell activation, their impact on multisystem clinical manifestations, and the rationale for targeted therapies clinical manifestations
2. Utilize updated diagnostic criteria and laboratory assessments, including molecular and ancillary testing, to differentiate indolent and other forms of SM for accurate disease classification and prognosis
3. Summarize clinical trial findings for emerging and established therapies, including FDA-approved treatments
4. Develop individualized treatment plans for patients with nonadvanced SM by incorporating clinical evidence, safety considerations, patient-reported outcomes, shared decision-making, patient education, and multidisciplinary management

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score at least 75% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Matthew P. Giannetti, MD: Consulting Fees: Blueprint Medicines, Cogent Biosciences, NemaGen Discoveries, Novartis AG; Other (Medical Safety Board): Immagene, Inc.

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.